Specialty Pharmacy

In a short time, COVID-19 has increased our dependency on technology and pharmaceutical companies are actively investigating this digital transformation.

Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.

The FDA approved an expanded label for for pembrolizumab for adult patients with relapsed or refractory classical Hodgkin lymphoma.

Copanlisib (Aliqopa) in combination with rituximab (Rituxan) prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

Despite it being fall, sun safety is important all year and even needs to be considered for winter sport activities, such as snowboarding and skiing.

Evidence-based cancer regimens have been shown to result in better outcomes, including longer survival and less toxicity.

Pacritinib is a JAK2/FLT3 inhibitor for the treatment of patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.

The COVID-19 pandemic has caused many routine colorectal cancer screenings to be delayed.

In the absence of a direct head-to-head clinical trial, study may help inform treatment selections for stem cell transplant-ineligible patients.

Enfortumab vedotin-ejfv (Padcev) elicited durable responses in patients with locally advanced or metastatic urothelial cancer who received previous treatment with a PD-1/PD-L1 inhibitor.

The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.

On Women Pharmacists Day, 5 industry leaders discuss work-life balance, job advancement, and mentorship.

Several risk factors for multiple sclerosis, such as disease progression and fatigue, increase the risk of unemployment.

Bacteria in the gut may play a role in the treatment outcomes of patients with prostate cancer taking oral medications, according to a recent study.

To celebrate American Pharmacists Month, Pharmacy Times spoke with several pharmacists about their experiences during the COVID-19 pandemic and how they have tackled its unique challenges.

Specialty pharmacies are uniquely positioned to thrive in the era of value-based health care.

During American Pharmacists Month, and as the country uses all available health care resources to address COVID-19, there has never been a better or more important time to grant provider status to pharmacists.

Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.

An overview of arrangements that pharmacies enter into that violate the federal anti-kickback statute.

Partnership will commemorate the event with a webinar and presentation of Woman Pharmacist of the Year award on Oct. 12.

Like diabetes, Inflammatory bowel disease may also be linked to a high-fructose diet.

IMGN632 granted breakthrough designation for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Integrating specialty pharmacy staff into oncology, neurology, rheumatology, and other specialty clinics within their health systems is a growing trend with a range of beneficial outcomes.

Nivolumab plus ipilimumab is the first immunotherapy approved for previously untreated unresectable malignant pleural mesothelioma.

During American Pharmacists Month, the National Association of Chain Drug Stores is honoring the role of pharmacists as the most accessible point of health care for patients, particularly among those in the greatest need.

Pharmacy Times will be celebrating pharmacists throughout the month of October to recognize their contributions to the health care field, especially in the ongoing coronavirus disease 2019 pandemic.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.